Plain-English translation of NCT06349512 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a new type of imaging scan called 68Ga-FAPI-46 PET/CT can predict how well women with triple-negative breast cancer will respond to treatment with pembrolizumab combined with chemotherapy. The scan would be done before treatment starts to help doctors understand which patients are most likely to benefit from this medication combination. This could help doctors personalize cancer care and improve outcomes.
Triple-negative breast cancer is a particularly aggressive form of breast cancer that doesn't respond to some common hormone-based treatments. Doctors need better ways to predict which patients will respond well to the new immunotherapy treatments, so they can plan the best care strategy early on.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will have a special imaging scan before starting treatment to help predict your response. Then you will receive the standard treatment plan: chemotherapy combined with pembrolizumab (an immunotherapy medication) before surgery, followed by surgery, and then additional immunotherapy after surgery. The study team will monitor your response to treatment and collect information about how well the medication worked.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
France